|
adult |
14 |
|
humans |
12 |
|
medical sciences |
12 |
|
acute myeloid leukemia |
11 |
|
arsenic trioxide |
10 |
|
male |
10 |
|
acute promyelocytic leukemia |
9 |
|
female |
9 |
|
myelofibrosis |
9 |
|
clofarabine |
8 |
|
cytarabine |
8 |
|
gastroenterology |
8 |
|
middle aged |
8 |
|
rituximab |
8 |
|
asia |
7 |
|
diagnosis, differential |
7 |
|
fludarabine |
7 |
|
oral arsenic trioxide |
7 |
|
prophylaxis |
7 |
|
azacitidine |
6 |
|
breakthrough invasive fungal infections |
6 |
|
echinocandin |
6 |
|
essential thrombocythemia |
6 |
|
hematology |
6 |
|
polycythemia vera |
6 |
|
acquired immunodeficiency syndrome - complications - diagnosis |
5 |
|
aged |
5 |
|
antifungal drug |
5 |
|
bone marrow - pathology |
5 |
|
bone marrow transplantation |
5 |
|
cryptococcosis - diagnosis - etiology |
5 |
|
dna methylation |
5 |
|
flt3-itd |
5 |
|
hodgkin disease - drug therapy - pathology |
5 |
|
leukaemia |
5 |
|
lymphatic diseases - diagnosis - etiology |
5 |
|
lymphoma - diagnosis |
5 |
|
lymphoma, large b-cell, diffuse - drug therapy - pathology |
5 |
|
maintenance |
5 |
|
mediastinal neoplasms - drug therapy - pathology |
5 |
|
mucosa-associated lymphoid tissue |
5 |
|
next-generation sequencing |
5 |
|
non-gastric marginal zone lymphoma |
5 |
|
post-transplant lymphoproliferative disorders |
5 |
|
primary |
5 |
|
prognosis |
5 |
|
recurrence |
5 |
|
secondary |
5 |
|
sorafenib |
5 |
|
splenic marginal zone lymphoma |
5 |
|
treatment failure |
5 |
|
aged, 80 and over |
4 |
|
alemtuzumab |
4 |
|
antigens, cd20 - metabolism |
4 |
|
bleomycin |
4 |
|
bone marrow |
4 |
|
chemotherapy-free |
4 |
|
cisplatin |
4 |
|
corticosteroid |
4 |
|
cyclophosphamide |
4 |
|
cyclosporin |
4 |
|
cytomegalovirus |
4 |
|
dexamethasone |
4 |
|
epstein barr virus |
4 |
|
gene expression |
4 |
|
genetic predisposition to disease |
4 |
|
haploinsufficiency |
4 |
|
hydroxyurea |
4 |
|
immunotherapy |
4 |
|
indolent lymphoma |
4 |
|
lymphoma, t-cell - immunology - pathology - radionuclide imaging |
4 |
|
marrow biopsy |
4 |
|
methotrexate |
4 |
|
mitoxantrone |
4 |
|
myelodysplastic syndromes - genetics - metabolism |
4 |
|
myeloproliferative neoplasms |
4 |
|
natural killer t-cells - immunology - pathology |
4 |
|
nose neoplasms - immunology - pathology - radionuclide imaging |
4 |
|
nuclear proteins - biosynthesis - genetics |
4 |
|
pet/ct |
4 |
|
positron-emission tomography |
4 |
|
prednisolone |
4 |
|
primary myelofibrosis |
4 |
|
promoter regions, genetic - genetics |
4 |
|
relapse |
4 |
|
reverse transcriptase polymerase chain reaction - methods |
4 |
|
rna, messenger - genetics |
4 |
|
standardized uptake value |
4 |
|
treatment |
4 |
|
valganciclovir |
4 |
|
vincristine |
4 |
|
young adult |
4 |
|
abdominal pain - etiology |
3 |
|
allogeneic |
3 |
|
allogeneic haematopoietic stem cell transplantation |
3 |
|
anemia, refractory - complications - diagnosis - pathology |
3 |
|
anemia, sideroblastic - complications |
3 |
|
autologous |
3 |
|
cd3 antigen |
3 |
|
cd4 antigen |
3 |
|
cd56 antigen |
3 |
|
cd8 antigen |
3 |
|
chinese |
3 |
|
copper - deficiency |
3 |
|
cytomegalovirus retinitis |
3 |
|
droplet digital polymerase chain reaction |
3 |
|
enteropathy-sssociated t-cell lymphoma - immunology - pathology - physiopathology - therapy |
3 |
|
epigenetic modifiers |
3 |
|
extranodal |
3 |
|
eye infections, viral - diagnosis - immunology - therapy |
3 |
|
fatal outcome |
3 |
|
fdg-pet/ct |
3 |
|
first completion remission |
3 |
|
flt3 |
3 |
|
gastrointestinal neoplasms - immunology - pathology - physiopathology - therapy |
3 |
|
gene mutations |
3 |
|
haematopoietic sct |
3 |
|
hematopoietic stem cell transplantation - adverse effects |
3 |
|
herpes zoster ophthalmicus - diagnosis - immunology - therapy |
3 |
|
immunocompromised host |
3 |
|
immunosuppression - adverse effects |
3 |
|
indolent |
3 |
|
intestinal obstruction - etiology |
3 |
|
intestinal perforation - etiology |
3 |
|
kit |
3 |
|
leukemia, myeloid, acute - therapy |
3 |
|
lymphoma |
3 |
|
lymphoma, extranodal nk-t-cell - complications - diagnosis |
3 |
|
mantle cell lymphoma |
3 |
|
measurable-residual disease |
3 |
|
monoclonal antibodies |
3 |
|
myelodysplastic syndrome |
3 |
|
myeloproliferative neoplasm |
3 |
|
npm1 |
3 |
|
opportunistic infections - diagnosis - immunology - therapy |
3 |
|
oral |
3 |
|
oral arsenic trioxide maintenance |
3 |
|
paraneoplastic syndromes - etiology - pathology |
3 |
|
pemphigus - etiology - pathology |
3 |
|
prognostication |
3 |
|
refractory |
3 |
|
relapsed |
3 |
|
retinal necrosis syndrome, acute - diagnosis - immunology - therapy |
3 |
|
second complete remission |
3 |
|
suv |
3 |
|
t-cell large granular lymphocyte leukaemia |
3 |
|
target therapy |
3 |
|
targeted treatment |
3 |
|
acute promyelocitic leukaemia |
2 |
|
acute promyelocytic leukemia (apl) |
2 |
|
advanced haematological malignancies |
2 |
|
anemia, sideroblastic - etiology - physiopathology - therapy |
2 |
|
anti-thymocyte globulin |
2 |
|
antifungal prophylaxis |
2 |
|
antithyroid agents - therapeutic use |
2 |
|
aplastic anaemia |
2 |
|
biopsy |
2 |
|
carbimazole - therapeutic use |
2 |
|
ciclosporin |
2 |
|
clinical applications |
2 |
|
consensus |
2 |
|
cost-effective |
2 |
|
cost-saving |
2 |
|
digeorge syndrome |
2 |
|
early death |
2 |
|
early palliative care (early pc) |
2 |
|
early pc |
2 |
|
eltrombopag |
2 |
|
epidemiology |
2 |
|
fluconazole |
2 |
|
graves disease - complications - diagnosis - immunology |
2 |
|
guidelines |
2 |
|
haematology palliative care |
2 |
|
history |
2 |
|
hypocalcemia |
2 |
|
hypomethylating agents |
2 |
|
immunoglobulins, intravenous - therapeutic use |
2 |
|
induction |
2 |
|
itraconazole |
2 |
|
kidney failure, chronic - diagnosis - therapy |
2 |
|
leukemia-free survival |
2 |
|
lymphoma, t-cell - complications - immunology |
2 |
|
neutropenia |
2 |
|
newly diagnosed |
2 |
|
newly diagnosed acute promyelocytic leukemia |
2 |
|
peritoneal dialysis, continuous ambulatory - adverse effects - methods |
2 |
|
pharmacokinetics |
2 |
|
posaconazole |
2 |
|
pyridoxine - deficiency |
2 |
|
randomized controlled trials (rct) |
2 |
|
relapsed acute myeloid leukemia |
2 |
|
renal dialysis - adverse effects - methods |
2 |
|
romiplostim |
2 |
|
supportive care |
2 |
|
symptom burden |
2 |
|
symptom management |
2 |
|
t-lymphocytes, cytotoxic - immunology |
2 |
|
tetraarsenic tetrasulfide |
2 |
|
thrombocytopenia - drug therapy - etiology |
2 |
|
all-trans retinoic acid |
1 |
|
ascorbic acid |
1 |
|
chronic myeloid leukemia |
1 |
|
clonal cytopenia of undetermined significance |
1 |
|
clonal hematopoiesis |
1 |
|
clonal hematopoiesis of indeterminate potential |
1 |
|
disease-modifying |
1 |
|
drug development |
1 |
|
early/lower risk pmf |
1 |
|
epigenome |
1 |
|
human |
1 |
|
mixed-phenotype leukemia |
1 |
|
myelodysplastic neoplasm |
1 |
|
myelodysplastic syndrome/neoplasm (mds) |
1 |
|
myelodysplastic syndromes |
1 |
|
myeloid sarcoma |
1 |
|
placebo controlled phase 3 |
1 |
|
pre-fibrotic pmf |
1 |
|
primary myelofibrosis (pmf) |
1 |
|
randomized |
1 |
|
rna-sequencing |
1 |
|
ropeginterfeon alfa-2b |
1 |
|
stem cells |
1 |
|
study population |
1 |
|
targeted therapy |
1 |
|
tcf3::znf384 |
1 |
|
therapies |
1 |
|
treatment resistance |
1 |
|
whole genome sequencing |
1 |
